









Markets
/
Stocks
/
nasdaq-bbio
/

BridgeBio Pharma Inc

BBIO

71.610USD

+3.080+4.49%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

13.95BMarket Cap

LossP/E TTM



BridgeBio Pharma Inc

71.610

+3.080+4.49%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BridgeBio Pharma Inc

Currency: USD Updated: 2026-03-25

Key Insights

BridgeBio Pharma Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 99.72.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BridgeBio Pharma Inc's Score

Industry at a Glance

Industry Ranking

18 / 157

Overall Ranking

65 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

BridgeBio Pharma Inc Highlights

StrengthsRisks

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 5296.93% year-on-year.

Undervalued

The company’s latest PE is -18.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 193.26M shares, increasing 0.14% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 671.00 shares of this stock.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

99.725

Target Price

+43.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of BridgeBio Pharma Inc is 7.48, ranking 103 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 154.18M, representing a year-over-year increase of 2521.18%, while its net profit experienced a year-over-year increase of 27.24%.

Score

Industry at a Glance

Previous score

7.48

Change



Financials

6.35

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.45

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.21

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.32

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BridgeBio Pharma Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of BridgeBio Pharma Inc is 6.77, ranking 112 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -18.92, which is -88.38% below the recent high of -2.20 and -3.78% above the recent low of -19.64.

Score

Industry at a Glance

Previous score

6.77

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 18/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of BridgeBio Pharma Inc is 8.61, ranking 21 out of 157 in the Pharmaceuticals industry. The average price target is 82.00, with a high of 110.00 and a low of 42.21.

Score

Industry at a Glance

Previous score

8.61

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

99.725

Target Price

+43.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

BridgeBio Pharma Inc

BBIO

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of BridgeBio Pharma Inc is 8.88, ranking 16 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 77.42 and the support level at 64.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.14

Change

1.74

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.784

Neutral

RSI(14)

53.747

Neutral

STOCH(KDJ)(9,3,3)

55.776

Buy

ATR(14)

3.227

High Vlolatility

CCI(14)

61.484

Neutral

Williams %R

34.976

Buy

TRIX(12,20)

-0.058

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

69.670

Buy

MA10

69.783

Buy

MA20

68.569

Buy

MA50

72.155

Sell

MA100

71.570

Buy

MA200

60.414

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of BridgeBio Pharma Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.83%, representing a quarter-over-quarter decrease of 2.22%. The largest institutional shareholder is The Vanguard, holding a total of 16.83M shares, representing 8.68% of shares outstanding, with 10.83% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

16.80M

+2.09%

Kohlberg Kravis Roberts & Co. L.P.

13.26M

Viking Global Investors LP

Star Investors

15.89M

-0.53%

BlackRock Institutional Trust Company, N.A.

11.92M

+0.24%

Janus Henderson Investors

8.74M

-5.77%

Farallon Capital Management, L.L.C.

8.19M

+3.70%

Kumar (Neil)

6.17M

Aisling Capital Management LP

6.09M

+0.35%

State Street Investment Management (US)

5.61M

-4.92%

Geode Capital Management, L.L.C.

3.91M

+6.20%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BridgeBio Pharma Inc is 6.86, ranking 46 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. BridgeBio Pharma Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.